Last reviewed · How we verify

NCT03074097

Rectus Sheath Block: Postoperative Analgesia and Proinflammatory Cytokines

Completed Phase 2 Last updated 22 February 2018
What this trial tests

Phase 2 trial testing Bupivacaine 0.25% in Postoperative Pain in 60 participants. Completed in 28 April 2016.

Timeline
5 March 2015
Primary endpoint
1 February 2016
28 April 2016

Quick facts

Lead sponsorAssiut University
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment60
Start date5 March 2015
Primary completion1 February 2016
Estimated completion28 April 2016
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

40 and older, any sex, with Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Good quality of postoperative analgesia would lead to attenuate or prevent the adverse effects on the common functions of the immune system. We compared the effect of epidural analgesia versus rectus sheath block on postoperative pain and proinflammatory cytokines following malignant urological surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Bupivacaine 0.25%

Trials testing the same drug.

Other recruiting trials for Postoperative Pain

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03074097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing